Octreotide Terminated Phase 2 Trials for Malignancies Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02294786Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer